{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-22-000082","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.710356+00:00","generated_at":"2026-06-21T23:53:25.531690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track","bullets":["Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.","Cash $444.8M provides runway into 2026; no additional draw on Oberland facility.","SerpinPC pivotal program: PRESent-5 observational study starting Q4 2022; Phase 2a OLE data at ASH Dec 10.","LB101 IND submission for PD-L1xCD47 bispecific on track for late 2022.","SerpinPC granted FDA Orphan Drug Designation in September 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-22-000082","json":"https://secwatch.observer/filing/0001847903-22-000082.json","markdown":"https://secwatch.observer/filing/0001847903-22-000082.md","text":"https://secwatch.observer/filing/0001847903-22-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/0001847903-22-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/cnta-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:53:25.531690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"177a3d2d601170201ea3e93c14f6fbd80aa8350f","claim":"Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2022 results: net income $53.9 million.","evidence_excerpt":"Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/0001847903-22-000082-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$53.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}